Рет қаралды 2,011
Dr. George L. Bakris reports that two aldosterone receptor blocking drugs spironolactone and eplerenone have swiftly become important, second-line antihypertensive drugs for obese patients. Mitchel Zoler of Elsevier Global Medical News (EGMN) reports from a meeting of the American Diabetes Association in New York.